Zhang Jun, Jiang Dazhen, Liu Hui, Shen Jiuling, Wang Dajiang, Chen Cheng, Xie Conghua, Cao Zhen
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Med Dosim. 2020;45(1):66-72. doi: 10.1016/j.meddos.2019.06.001. Epub 2019 Jul 8.
The aim of this study was to generate a local confidence limit (CL) for intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) techniques for Clinac IX linear accelerator using the American Association of Physicists in Medicine (AAPM) Task Group (TG119) protocol. The results were compared with the published studies to test the capability and quality of the VMAT technique in our clinic. We used TG119 cases to create plans for IMRT and VMAT in Eclipse Treatment Planning System for Clinac IX using 6 MV and 10 MV photons. Two preliminary and 5 clinical test cases were created based on the dose prescriptions and planning objectives provided by TG119. Verification plans were created in a planning slab phantom, 2D matrix dosimetry system (MatriXX) with multicube phantom and a volumetric phantom (Delta). Radiation absorption doses to high-dose points in the planning target volume region and low-dose points in avoidance structures were measured with a 0.125 cc semiflex thimble ionization chamber (PTW). The measured and planned doses were normalized with respect to their prescription doses and intercompared with each other. The gamma analysis was carried out for MatriXX and Delta adopting the acceptance criteria of 3% dose difference and 3 mm distance to agreement with 10% threshold dose, respectively. The local CLs with the bench mark set by TG119 were obtained for point, composite planar and field-by-field measurements for IMRT and VMAT with different energies. In this study, the CLs for the high-dose regions of IMRT with 6 MV and 10 MV were 0.025 and 0.014, respectively. For VMAT, they were 0.032 and 0.018. The counterpart CL was 0.045 in TG119. And in organs at risk region, the CLs of IMRT with 6 MV and 10 MV beam were 0.022 and 0.019, respectively, with the counterpart CL indicated by TG119 was 0.047. For VMAT with 6 MV and 10 MV photon beams, the CLs were measured 0.030 and 0.027 with Delta, respectively. The CLs of the maximum gamma passing for all values were 2.0 in 6 MV VMAT plan, which however recommended in TG119 was 12.4. The data presented here showed all the CLs in our clinic meet the criteria of TG119 report well. All these local CLs reached the goals mentioned in AAPM TG119, which indicated that the local clinic had commissioned IMRT and VMAT techniques with adequate accuracy. Prior to the clinical application practice, it is essential to verify with the TG119 test cases for IMRT and VMAT, which allows us to better understand the basic capability of VMAT technology.
本研究的目的是使用美国医学物理学家协会(AAPM)任务组(TG119)方案,为Clinac IX直线加速器的调强放射治疗(IMRT)和容积调强弧形治疗(VMAT)技术生成局部置信限(CL)。将结果与已发表的研究进行比较,以测试我们诊所VMAT技术的性能和质量。我们使用TG119病例,在Eclipse治疗计划系统中为Clinac IX创建IMRT和VMAT计划,使用6 MV和10 MV光子。根据TG119提供的剂量处方和计划目标,创建了两个初步病例和5个临床测试病例。在计划平板体模、带有多立方体体模的二维矩阵剂量测定系统(MatriXX)和容积体模(Delta)中创建验证计划。使用0.125 cc半柔性指形电离室(PTW)测量计划靶区高剂量点和避让结构低剂量点的辐射吸收剂量。将测量剂量和计划剂量相对于其处方剂量进行归一化,并相互比较。对MatriXX和Delta进行伽马分析,分别采用3%剂量差异和3 mm距离一致性以及10%阈值剂量的验收标准。获得了不同能量的IMRT和VMAT在点、复合平面和逐野测量中以TG119设定的基准为标准的局部CL。在本研究中,6 MV和10 MV的IMRT高剂量区的CL分别为0.025和0.014。对于VMAT,分别为0.032和0.018。TG119中的对应CL为0.045。在危及器官区域,6 MV和10 MV射束的IMRT的CL分别为0.022和0.019,TG119指出的对应CL为0.047。对于6 MV和10 MV光子束的VMAT,使用Delta分别测量到的CL为0.030和0.027。6 MV VMAT计划中所有值的最大伽马通过率的CL为2.0,而TG119中推荐的值为12.4。此处给出的数据表明,我们诊所的所有CL均很好地符合TG119报告的标准。所有这些局部CL均达到了AAPM TG119中提到的目标,这表明当地诊所已以足够的精度启用了IMRT和VMAT技术。在临床应用实践之前,必须使用IMRT和VMAT的TG119测试病例进行验证,这使我们能够更好地了解VMAT技术的基本性能。